High expression of RARG accelerates ovarian cancer progression by regulating cell proliferation

Lin Xiu¹, Yuxi Zhao¹, Ning Li¹, Jia Zeng¹, Jing Liu¹, Yongliang Fu², Qiao Gao³ and Lingying Wu¹*  
¹Department of Gynecology Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

Purpose: To explore the relationship between retinoic acid receptor gamma (RARG) and ovarian cancer (OC) cell proliferation and the prognosis of patients.

Methods: The transcriptome and clinical information of 379 OC and 88 normal ovarian samples were downloaded from the Cancer Genome Atlas (TCGA) database and the Genotype Tissue Expression (GTEx) database. We compared the mRNA level of RARG between ovarian normal and tumor tissues with the Wilcoxon rank sum test. The R package "limma" was used to analyze the differences in RARG expression between different clinical subgroups. Kaplan−Meier analysis was applied to evaluate the correlation between RARG and prognosis of patients. A nomogram was established to predict the effect of RARG on prognosis of OC patients. Immunohistochemistry and qRT−PCR experiments were conducted to determine the differential expression of RARG between ovarian normal and tumor tissues. Finally, we altered RARG expression using specific siRNA and lentiviral expression vectors to explore the function of RARG by CCK-8, cell cycle, colony formation, and xenograft assays in nude mice.

Results: RARG was highly expressed in ovarian tumors and was an independent predictor of poor overall survival outcomes. Subgroup analysis showed the high expression of RARG was related to FIGO stage III-IV (P=0.027), overall survival time <5 years (P=0.013) and dead status (P=0.041). The Kaplan−Meier curve indicated that patients with high RARG expression level had poor prognosis. The area under the curve (AUC) of RAGR expression for predicting patient survival rates at 1, 5 and 9 years were 0.659, 0.616 and 0.627, respectively. The GSEA enrichment analysis revealed that RARG was involved in ovarian cancer progression through multiple pathways. In cellular experiments in vitro, downregulation of RARG expression significantly suppressed the proliferation and colony formation capacity of OC cells. In cellular experiments in vivo, knockdown of RARG significantly reduced tumor
growth in nude mice, decreased expression levels of Ki-67 and proliferation cell nuclear antigen (PCNA).

Conclusions: High expression of RARG could promote OC cell proliferation and was an independent predictor of poor prognosis. RARG might work as a potential molecular target and biomarker for individualized diagnosis and treatment in OC patients.

KEYWORDS
RARG, ovarian cancer, prognosis, cell proliferation, biomarker

Introduction

Ovarian cancer (OC) is the third most common malignant tumor of the female reproductive system (1, 2). There are approximately 225,000 new cases in the world every year (3). Although the 5-year survival rate for patients with early-stage ovarian cancer can be varied from 60% to 90%, while advanced OC could be an insidious disease with high mortality (4). At present, effective predictive biomarkers for clinical diagnosis and treatment strategies are urgently needed.

OC is a highly heterogeneous disease, and differentiation based on stage alone is not sufficient for clinical diagnosis (5). Therefore, there is an urgent need to explore and establish a classification method combining molecular phenotypes with clinicopathological features to better guide the clinical treatment, prognosis prediction and individualized treatment of patients. To date, several targeted therapies have been used in OC treatments. For example, PARP inhibitor, the first drug targeting the DNA damage response to have entered the clinic, represents a successful example of molecular target therapy.

Retinoic acid receptors (RAR) are members of the nuclear receptor superfamily that mediate the multipotent effects of the vitamin A metabolite retinoid and its derivatives in normal and cancer cells (6, 7). RAR is encoded by three distinct genes, α, β, and γ (8). Retinoic acid receptor γ (RARG), which is 90% homologous to retinoic acid receptor α (RARA) and retinoic acid receptor β (RARB), is unique among the three RAR subtypes because it typically resides in the cytoplasm of cancer cells (9). Studies have found that RARG plays a vital role in the occurrence and development of many tumors, such as hepatocellular carcinoma, esophageal carcinoma and prostate cancer, and its expression level is closely related to the proliferation and migration ability of tumor cells (10–12). However, the role of RARG in the occurrence and development of ovarian cancer is still unclear.

Using bioinformatics and molecular biology techniques, we performed the present study to explore the function of RARG on OC and to evaluate its correlation with the prognosis of OC patients. Our study used TCGA and GTEx database to calculate RARG expression in ovarian cancer tissues and normal ovarian tissues. The function of RARG on cell proliferation, cell cycle and colony formation ability were investigated by using specific siRNA and lentiviral expression vectors in two OC cell lines. The highlight was that we further used xenograft assays in nude mice to confirm the role of RARG in OC.

Materials and methods

Data collection and processing

The clinical information and mRNA expression data of 379 OC patients were collected from The Cancer Genome Atlas (TCGA) database, and the gene expression profiles of 88 normal ovarian samples were obtained from the Genotype Tissue Expression (GTEx) database. Normalized gene expression was measured as fragments per kilobase of transcript per million mapped reads (FPKM), and the values were log2-transformed.

RARG differential expression and prognosis correlation

The correlations between mRNA level of RARG and tissues were analyzed by Wilcoxon rank sum test. Based on different clinical subgroups, the differential expression of RARG was calculated by the R package “limma”. According to the expressed median value of RARG, the OC patients were divided into a RARG-high expression group and a RARG-low expression group. Kaplan–Meier survival analysis was performed by the “Survival” R package to evaluate the difference in survival rates between the two groups. The area under time-dependent receiver operating characteristic (ROC)
curve was used to evaluate the prediction efficiency of RARG by the R package “survival ROC”.

Construction and validation of a nomogram incorporating RARG

We sequentially conducted univariate and multivariate Cox regression analyses to identify the association of RARG with OC prognosis. To accurately and intuitively predict the prognosis of patients, a nomogram was constructed based on RARG and clinical features using the R package “rms”. The consistency between the actual survival rates and the nomogram-predicted rates was determined using calibration plots to evaluate the calibration of the nomogram.

Functional enrichment and analysis of immune cell infiltration

We took the absolute value of correlation coefficient greater than 0.3 as the threshold to screen RARG related genes (Supplementary Excel 1). Based on the above genes, we performed GO enrichment analysis via the “clusterProfiler” package to explore the function of RARG. We screened the differentially expressed genes in RARG-high expression group and RARG-low expression group with logFC greater than 0.2 and P < 0.05. Then GSEA (www.gsea-msigdb.org/gsea/index.jsp) was utilized to assess these gene sets to determine if the identified sets had significant differences. We set |Normalized enrichment score (NSE)|>1, nominal (NOM) p value < 0.05 and FDR q-value < 0.25 as the cutoffs.

The relative tumor infiltration levels of 22 immune cell types were determined by ssGSEA. The difference in immune cell abundance between the RARG-high expression and RARG-low expression groups was analyzed by the “limma” R software package.

Tissue specimens

20 OC tissues and 10 normal ovarian tissues were collected from patients who underwent surgical resection in National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (from September 2016 to August 2017). Pathologists immediately isolated tissue from each patient and stored it in liquid nitrogen. Three pathologists confirmed the pathological examination of ovarian cancer. Ethical approval was provided by the Ethics Committee of the Cancer Institute (Hospital), CAMS&PUMC (21/146-2817).

Cell culture and transfection

The human OC cell lines A2780 and SKOV3 were provided by the Cell Resource Center (IBMS, CAMS/PUMC). Both cell lines were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (Invitrogen, San Diego, CA) at 37°C with 5% CO₂. We synthesized small interfering RNA (siRNA) against human RARG and control nonsilent siRNA (GenePharma Shanghai, China). The siRNAs were transfected with Lipofectamine 2000 (Invitrogen, San Diego, CA, USA) according to the kit instructions, and the final concentration used for RARG silencing was 50 nM. A lentiviral vector PLKO.1-shRARG-GFP knocking out RARG was constructed by GenePharma. To generate the lentivirus, 293FT cells were cotransfected with psPAX2, pMD2G and PLKO.1-shRARG-GFP. 48 hours after transfection, the lentiviral supernatants were collected and filtered through a 0.22 μm filter. The filtered lentivirus was incubated with polybrene (Sigma, St Louis, MO, USA) and transfected into ovarian cancer cells, and then the cells were screened with puromycin (0.8 μg/ml, Invitrogen) for 72 hours. The sequences of siRNAs and shRNAs are listed in Table 1.

Total RNA extraction, quantitative real-time PCR, western blot and immunohistochemistry

The samples for qRT-PCR was extracted from 10 pairs of OC tissues and adjacent normal tissues frozen in liquid nitrogen with TRizol reagent (Invitrogen, Carlsbad, CA, USA). Following the manufacturer’s instruction, total RNA was isolated using an RNeasy Tissue & Cell Kit (Cwbiotech, Beijing, China). The isolated RNA was used as a template for reverse transcription reactions using a HiFiScript cDNA Synthesis Kit (Cwbiotech). Quantitative real-time RT–PCR (qRT-PCR) analysis was performed using SYBR® Fast qPCR Mix (TaKaRa, Shiga, Japan) and a CFX96 Real-Time System (Bio-Rad). The primer sequences are shown in Table 2. GAPDH served as an internal control. Each samples were performed independently for three times.

Total protein was isolated from tissue samples by using RIPA buffer (Applygen, Beijing, China) with protease inhibitors (Roche, Basel, Switzerland). Immunoblotting was performed

| Groups | Sequences |
|--------|-----------|
| Non-silencing | 5'-TTCTCCGAACGTTCTACGT-3' |
| RARG -siRNA-1 | 5'-CCTTCAGTATCTGACGAAGT-3' |
| RARG -siRNA-2 | 5'-CCTTCAGTATCTGACGAAGT-3' |
| RARG -shRNA | 5'-CAATGCAAGTCTGTGCTA-3' |
with primary antibodies against RARG (1:1000, Proteintech, Wuhan, China). GAPDH (1:5000, Proteintech) was used as a loading control. Secondary antibodies (goat anti-mouse IgG and goat anti-rabbit IgG, 1:5000) were purchased from Applygen. The signals were visualized with a super enhanced chemiluminescence (ECL) detection reagent (Applygen).

For immunohistochemistry, a total of 20 OC tissues and 10 normal ovarian tissues that were embedded in paraffin were collected from patients who underwent surgical resection in CAMS hospital, China (from September 2016 to August 2017). 4-μm-thick sections of paraffin-embedded tissue arrays were deparaffinized in xylene, rehydrated in graded ethanol and incubated in 3% hydrogen peroxide in methanol to block endogenous peroxidase. The sections were then heated for 20 min in 0.01 mol/l citrate buffer (pH 6.0) in a microwave oven. After washing the sections with PBS 3 times, they were incubated with an anti-human RARG antibody (1:500 dilution; Proteintech, Wuhan, China) at 4°C overnight. After washing in PBS, the sections were developed according to the manufacturer’s instructions (PV-9000 Polymer Detection System, ZhongShan Golden Bridge, China), counterstained with hematoxylin, dehydrated in graded ethanol and sealed with neutral resin. For immunohistochemistry in the xenografts resected from nude mice, experimental process was similar with primary antibodies including anti-RARG antibody (1:500 dilution; Proteintech), anti-Ki67 antibody (1:200 dilution; Abcam) and anti-Proliferating Cell Nuclear Antigen (PCNA; 1:300 dilution; CST). Two pathologists used 200x light microscopy to evaluate the immunostaining.

**Cell viability assay and colony formation assay**

According to the manufacturer’s protocol, the Cell Counting Kit-8 assay (CCK-8, Dojindo, Japan) was used to evaluate the effect of RARG on cell proliferation of A2780 and SKOV3. Each well seeded 1×10³ transfected cells in 96-well plates. For 7 consecutive days, adding 10μL CCK8 solution to each well every 24 h. After incubating in 37°C with 5% CO₂ for 1h, the absorbance at 450 nm measured by an automatic microplate reader (BioTek, Winooski, VT, USA) was used to read the optical density (OD) value. The relative cell viability (%) was finally calculated.

After RARG knockdown, 500 cells were seeded in each well of a six-well plate to evaluate the effect of RARG on cell clonogenesis. The cells were grown for 10-14 days to form colonies, which were then fixed with methanol and stained with crystal violet. The colonies were counted.

**Cell cycle analysis**

The cell cycle distribution of 1.0×10⁶ RARG-knockdown cells and 1.0×10⁶ negative control cells were fixed with 70% ethanol at 4°C overnight. The cells then were resuspended and analyzed by a cell cycle detection kit (KeyGen Biotech, Nanjing, China) and BD™ LSRII flow cytometry (BD Biosciences, San Jose, CA, USA). The cell cycle curves were analyzed by ModFit software (Verity Software House, Topshem, ME, USA).

**Xenograft model antitumor assay**

Animal experiments were approved by the Animal Center of the National Cancer Center/Cancer Hospital Research Institute of the Chinese Academy of Medical Sciences (NCC2021A-002). Ten 4-weeks-old female nude mice (BALB/C-NU, HFK Bioscience, Beijing, China) were randomly divided into two groups. All mice were raised in a special conditions under 12/12 cycle of light with 25-27°C temperature. Feed all mice with enough food and water as animal’s feeding guideline. A total of 3×10⁷ sh-RARG A2780 cells and 3×10⁷ sh-Scramble A2780 cells were injected subcutaneously into both groups. The tumor volume V was calculated by measuring the tumor size every 3 days. The formula was as follows: V= π/6(L×W²) (L: the length of the tumor, W: the width of the tumor). At the end of the experiment, used inhalational anesthesia with 2% isoflurane to sacrifice the mice, and followed by cervical dislocation. The tumor tissues were further resected and weighed. To confirm the differences in the protein expression levels of RARG, ki-67 and PCNA between sh-RARG group and sh-Scramble group, the tumor tissues were embedded in paraffin and sectioned for immunohistochemistry.

| Gene   | Primer | Sequence                              |
|--------|--------|---------------------------------------|
| GAPDH  | Forward | 5'-CAGCCTCAAGATCATCAGCA-3'             |
|        | Reverse | 5'-TGTTGTCATGACTCCCTCCA-3'            |
| RARG   | Forward | 5'-AAACAGGTAACCAGGATCAG-3'            |
|        | Reverse | 5'-TGTCAGGTGACCCCTCTTCC-3'            |

**TABLE 2** Primers for qRT–PCR analysis.
Statistical analysis

All statistical analyses were performed by R software 3.5.3 and SPSS 22.0 software. Chicago, IL, USA). All expression data were performed mean ± standard deviation. Differences between two groups were analyzed by Student's t-test, and differences between three or more groups were analyzed by ANOVA. The survival analysis was performed using Kaplan-Meier curves, and the differences between curves were verified using the log-rank test for OS. The independent prognostic factors were analyzed by the univariate and multivariate Cox regression models. P < 0.05 was considered statistically significant.

Results

The mRNA level of RARG was highly elevated in tumor tissues of OC patients

Firstly, we compared RARG mRNA level in 88 normal ovarian samples from the GTEx dataset with that in 379 OC samples from the TCGA dataset. The clinical characteristics and RARG expression data of 379 primary OC patients were shown in Table 3. The median age at diagnosis was 59 years old. In our study cohort, 0.26% of the tumors were well differentiated, 11.85% were moderately differentiated, and 85.20% were poorly or not differentiated. There was 1 patient (0.26%) of stage I primary OC, 23 patients (6.06%) of stage II OC, 295 patients (77.84%) of stage III OC, and 57 patients (15.04%) of stage IV OC. Of the subjects who were alive at the last follow-up, the median survival time was 797 days (range: 8-5481 days). The mean RARG of normal ovarian samples and OC samples were 3.11 and 4.27, respectively. The results demonstrated that compared with normal ovarian samples, RARG was significantly overexpressed in OC cells (p<0.001, Figure 1A).

Second, we searched for gene alterations of RARG on the cBioPortal website (Figure 1B). It revealed that 1.5% of patients with OC had RARG gene alterations, including amplification and gene mutations.

RARG mRNA levels in different clinical subgroups

To explore the correlation between RARG and clinico-pathological parameters, we excluded patients with unknown tumor stage, tumour grade and treatment outcomes. A total of 362 OC samples with complete RARG expression data and clinico-pathological characteristics from the TCGA dataset were analyzed. As shown in Figure 1C, D, there was no significant difference in RARG mRNA levels between subgroups of age (p = 0.297) and grade (p = 0.178). However, the RARG mRNA level was correlated with the pathologic stage of OC patients, the mean value of RARG in stage III-IV patients and stage-I-I patients were 4.64 and 4.27, which the level in stage III-IV patients was higher than that in stage-I-I patients (Figure 1E, p<0.05). The RARG mRNA level in patients with survival time less than or equal to 5 years was higher than that in patients with survival time greater than 5 years (Figure 1F, p<0.05). The RARG mRNA level in patients who died was higher than that in patients who survived (Figure 1G, p<0.05).

Elevation of RARG mRNA level was positively correlated with poor prognosis

To further explore the relationship between RARG mRNA level and prognosis of OC patients, we excluded patients with unknown prognostic information and 375 OC patients were enrolled. Based on the median value of RARG expression, 375 OC patients were divided into 187 RARG-high expression patients and 188 RARG-low expression patients. The Kaplan-Meier survival curves indicated that patients with high RARG expression had poorer prognosis (Figure 2A, p < 0.001). The prognostic assessment effect of RARG in OC samples was

| Characteristics | Number of sample size (%) |
|-----------------|---------------------------|
| Age (years)     |                           |
| <60             | 199 (52.51)               |
| >=60            | 180 (47.49)               |
| Histologic grade|                           |
| Grade 1         | 1 (0.26)                  |
| Grade 2         | 45 (11.85)                |
| Grade 3         | 322 (84.94)               |
| Grade 4         | 1 (0.26)                  |
| NA              | 10 (2.6)                  |
| TNM Stage       |                           |
| Stage I         | 1 (0.26)                  |
| Stage II        | 23 (6.06)                 |
| Stage III       | 295 (77.84)               |
| Stage IV        | 57 (15.04)                |
| NC              | 3 (0.80)                  |
| Therapy outcome |                           |
| Complete remission| 213 (56.20)             |
| Partial remission| 43 (11.35)               |
| Progressive disease | 27 (7.12)             |
| Stable disease  | 22 (5.80)                 |
| NA              | 74 (19.53)                |
| Vital status    |                           |
| Living          | 147 (38.79)               |
| Deceased        | 232 (61.21)               |

NA not available.
analyzed by ROC curve analysis. The areas under the curve (AUCs) of RARG for predicting 1, 5 and 9 year survival were 0.659, 0.616 and 0.627, respectively (Figure 2B).

To further evaluate the prognostic predictive effect of RARG, we performed Kaplan-Meier survival analyses based on different clinical subgroups. The Kaplan-Meier survival curve showed that patients with high RARG expression in the age <60 (Figure 2C, p < 0.05), age ≥60 (Figure 2D, p < 0.05), grade 1-2 (Figure 2E, p < 0.05), grade 3 (Figure 2F, p < 0.05) and stage III-IV (Figure 2H, p < 0.01) subgroups had a poor prognosis. In stage I-II subgroup, high RARG expression had no statistically significance with poor prognosis (Figure 2G, p > 0.05). These results indicated that high expression of RARG is positively associated with poor prognosis in most clinical subgroups, suggesting that elevated RARG might be a good biomarker for predicting the prognosis of OC patients.

Establishment and validation of a nomogram based on RARG

We performed univariate Cox regression and multivariate Cox regression to assess the independent prognostic value of clinicopathological parameters (age, stage and grade) and RARG derived from the TCGA set (Figures 3A, B). The multivariate Cox regression analysis showed that the HR value of RARG was 1.326 (Figure 3B, p < 0.01), which indicated that RARG was an independent risk factor for the prognosis of OC patients.

To provide an accurate classifier for predicting the prognosis of OC patients, we constructed a nomogram incorporating RARG and age (Figure 3C). The results showed that the calibration curves for 1-, 3- and 5-year survival rates were close to the standard curves, indicating that the nomogram had good prediction performance (Figure 3D).
Functional enrichment analysis of RARG in OC

Subsequently, gene-ontology (GO) enrichment analysis was performed for RARG related genes (Figure 4A). The biological process of GO enrichment included negative regulation of protein polymerization and the molecular function of enrichment included transcription coregulator activity. As shown in Figures 4B–G, the most related genes of RARG were SP1 (p < 0.001), STAT6 (p < 0.001), R3HDM2 (p < 0.001), HDAC7 (p < 0.001), ATF7 (p < 0.001) and M8D6 (p < 0.001). Subsequently, we performed GSEA enrichment analysis on genes differentially expressed between high and low RARG expression groups. The results of GSEA enrichment analysis showed that cAMP signaling pathway, Axon guidance, PI3K-Akt signaling pathway, Osteoclast differentiation, Focal adhesion, Proteoglycans in cancer, Human papillomavirus infection, Breast cancer, Regulation of actin cytoskeleton and Tight junction were positively correlated with the high expression of RARG (Figures 5A–K), while Non-alcoholic fatty liver disease (NAFLD), Oocyte meiosis, Purine metabolism, Thermogenesis, Huntington disease, Parkinson disease, Oxidative phosphorylation, Cell cycle, Spliceosome and Ribosome were negatively correlated with the high expression of RARG (Supplementary Figures 1A–J). The results indicated that the progression of ovarian cancer can be regulated through multiple pathways by high expression level of RARG.
Analysis of immune cell infiltration in high and low RARG expression group

To explore the differences in immune cell infiltration between high and low RARG expression groups, we first mapped the immune cell infiltration of each ovarian cancer patient in the TCGA cohort (Figure 6A). The infiltration degree of CD4 memory activated T cells (Figure 6B, p < 0.05) and Neutrophils (Figure 6B, p < 0.05) in RARG low expression group was higher than that in RARG high expression group.

Downregulation of RARG inhibited OC cell proliferation in vitro and in vivo

We applied qRT–PCR and immunohistochemistry to additionally confirm the differences in the mRNA expression levels and protein expression levels of RARG between ovarian cancer tissues and adjacent normal tissues. We used qRT–PCR which total RNA was extracted from 10 pairs of OC tissues and adjacent normal tissues to investigate the articulation verbalization of RARG at the mRNA transcriptional level. The results showed mRNA expression levels of RARG in ovarian cancer tissues were higher than adjacent normal tissues (Figure 7A). We further used immunohistochemistry to measure the RARG protein levels obtained from OC tissues and adjacent normal tissues. The results showed that RARG protein levels were higher in OC tissues than that in adjacent normal tissues (Figure 7B).

To clarify the functional role of RARG in OC cells, we applied RARG-siRNA to reduce its protein expression levels both in A2780 and SKOV3 cells (Figure 7C). Cell proliferation was detected by CCK-8 assay. The downregulation of RARG expression significantly suppressed the proliferation (Figure 7D, p < 0.001) and colony formation capacity of A2780 cells and SKOV3 cells (Figure 7F, p < 0.001). Cell cycle was not
significantly different between the RARG siRNA group and the negative control group (Figure 7E). Collectively, these data revealed that RARG could facilitate the proliferation and colony ability of OC cells in vitro.

In addition, western blot assay showed that sh-RARG stably knocked out RARG protein expression in A2780 cells and SKOV3 cells (Figure 8A). The CCK-8 assay results showed that the sh-RARG reduced the proliferation (Figure 8B, p < 0.001) and colony formation capacity (Figure 8C, p < 0.001) of A2780 cells and SKOV3 cells compared with the sh-Scramble group. Furthermore, in order to clarify the promoting effect of RARG on ovarian cancer cells in vivo, we used sh-RARG group (n=5) and sh-Scramble group (n=5) of A2780 cells to inoculate nude mice subcutaneously. Each mouse was inoculated with 4 million cells and successfully constructed the xenografted tumor mouse model. The formation of measurable tumors in nude mice was first detected on the 11th day after tumor cell inoculation, which was counted as the first day of measurement. In subsequent experiments, the body weight and volume of nude mice were counted every 3 days. On the
19th day of measurement, the mean volume of transplanted tumors in the sh-RARG group and sh-Scramble group were 190.400 mm³ and 627.600 mm³, respectively. The volume of transplanted tumors in the sh-RARG group was significantly reduced compared with that in the sh-Scramble group. Later, we dissected and weighed the transplanted tumor in nude mice. It was found that the average transplanted tumor in the sh-RARG and sh-Scramble group were 0.271 g and 0.738 g. The weight of transplanted tumor also decreased significantly after RARG knockout. The changes in tumor volume and weight in the nude mice are shown in Figure 8D. The results showed that the volume and weight of transplanted tumors were significantly reduced after RARG knockout. The immunohistochemistry results showed that compared with the sh-Scramble group, protein expression levels of RARG, Ki-67 and PCNA were significantly decreased in the sh-RARG group (Figure 8E).
Discussion

OC is one of the most common malignancies worldwide. OC has an insidious onset and lacks effective early screening and typical clinical symptoms, so approximately 70% of patients are already in an advanced stage at the time of diagnosis (13). In addition, OC easily invades and metastasizes, is difficult to cure by surgery and easily relapses after surgery (14). Tumor resection and postoperative platinum (cisplatin) combined with paclitaxel chemotherapy is the standard treatment for OC. However, chemotherapy not only easily produces drug resistance but also causes serious toxicity and side effects in patients, resulting in poor clinical treatment effects and poor prognosis (15). At present, a large number of molecules have been detected and identified as biomarkers related to the development and prognosis of OC. Clinically, the serological detection marker CA125 is often used in the diagnosis, efficacy evaluation and recurrence monitoring of OC, but the sensitivity and specificity of the diagnosis of early ovarian cancer is low, and it is susceptible to a variety of factors (16). Human testosterone protein 4 (HE4) can be used in the early diagnosis of OC with high sensitivity and specificity, but it still needs further clinical validation (17). Therefore, there is an urgent need to find more reliable biomarkers for the early diagnosis and targeted therapy of OC.

In this study, bioinformatics analysis showed that the mRNA level of RARG was increased in ovarian cancer tissues, and high expression of RARG was an independent predictor of poor prognosis, suggesting that RARG could be used as a molecular marker for the diagnosis and prognosis of OC. GO enrichment analysis of RARG-related genes showed that RARG may mediate transcription coregulator activity molecular functions, and the most relevant genes included SP1,STAT6,ATF7 and HDAC7. It suggested that RARG might affect the progression of ovarian cancer cells by participating in transcriptional regulation. Cell biology experiments showed that RARG knockdown attenuated...
FIGURE 7
Downregulation of RARG inhibited proliferation of OC cells. (A) The qRT-PCR analysis of RARG mRNA levels in ovarian tumor tissues and adjacent normal tissues. (B) Immunohistochemistry analysis of RARG protein levels in ovarian tumor tissues and adjacent normal tissues. (C) Western blotting analysis of RARG expression in A2780 cells or SKOV3 cells transfected with RARG siRNA or non-silencing siRNA. (D) Cell proliferation was detected by the CCK-8 assay. (E) Cell cycle assay. (F) Cell Colony assay. *P < 0.05; ***P < 0.001.
Knocking out RARG inhibited proliferation of OC cells. (A) Western blotting analysis of RARG expression in A2780 cells or SKOV3 cells transfected with RARG shRNA or scramble shRNA. (B) Cell proliferation was detected by the CCK-8 assay. (C) Cell Colony assay. (D) The xenograft tumors, tumor growth curve and weight of xenograft tumors. (E) Immunohistochemistry analysis of RARG, Ki-67 and PCNA protein levels in sh-Scramble group and sh-RARG group. Scale bar = 1 cm. **P < 0.01; ***P < 0.001.
the proliferation and clonogenesis of ovarian cancer cells in vitro, and knocking out RARG protein expression significantly inhibited the growth of ovarian tissue in vivo. Notably, RARG can be used not only as a prognostic biomarker, but also may be a molecular target for targeted therapy of OC.

RARG is also closely related to the occurrence and development of other tumors (18). RARG can act as an oncogene or a tumor suppressor gene and plays different roles in different tumors. On one hand, RARG is significantly overexpressed in hepatocellular carcinoma, esophageal carcinoma, cholangiocarcinoma, colon cancer and other human cancers and plays an important role in promoting tumor progression through the PI3K/Akt, NF-κB, Wnt/β-catenin and other signaling pathways (19–23). On the flip side, RARG can also be a tumor suppressor that inhibits the proliferation and invasion of cancer cells. RARG can inhibit the invasive ability of melanoma by regulating the expression of carboxywater transferase 10 (24). Loss of RARG expression can promote v-Ha-Ras-induced squamous cell carcinoma (25). Recent studies have reported that the expression of RARG is decreased in colorectal cancer tissues, suggesting that RARG could be used as a tumor suppressor gene to regulate the metastasis of colorectal cancer by inhibiting the Hippo-YAP signaling pathway (26). In addition, Brown G was reported RARG is selectively expressed in hematopoietic stem cells and their immediate progeny (27). RARG knockout mice display markedly reduced numbers of HSCs, which is critical for maintaining a balance between hematopoietic stem cell self-renewal and differentiation (28). RARG activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway (29). Researchers have developed small molecule inhibitors of RARG, the RARG selective antagonist AGN205728 can induce apoptosis through the mitochondria dependent pathway (12, 30). In conclusion, as an effector molecule, RARG plays an important role in ovarian cancer tumor cell proliferation and immune regulation. This study is also the first to report that RARG can act as an oncogene to promote ovarian cancer progression.

This study improves our understanding of the clinico-pathological significance and molecular pathogenesis of OC, we also need to conduct further research and deeply explore the mechanism of RARG in promoting the proliferation of ovarian cancer cells. Future work should be emphasized on studying more tissue samples to verify the bioinformatics results and developing small-molecule inhibitors to explore RARG for translational research.

**Conclusion**

In summary, we found that RARG was overexpressed in OC tissues and was an independent prognostic indicator for OC. The results demonstrated that elevated RARG could effectively accelerated cell proliferation and colony ability of OC cells in vitro and vivo. Our study indicated that RARG may become a biomarker and therapeutic target for individualized diagnosis and treatment of OC in the future.

**Data availability statement**

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

**Ethics statement**

The studies involving human participants were reviewed and approved by Ethics Committee of the Cancer Institute (Hospital), CAMS&PUMC (2021020814242902). The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by Animal Center of the National Cancer Center/Cancer Hospital Research Institute of the Chinese Academy of Medical Sciences (NCC2020C-462).

**Author contributions**

LX was responsible for the design and critical revision of the article. YZ modified and polished the description of the article. NL completed the data collection, and JL helped to draft and critically revise this report. JZ was responsible for data analysis. YF and QG analyzed the newly added experimental data. LW prepared the figures and tables. All authors contributed to the article and approved the submitted version.

**Funding**

Beijing Hope Run Special Fund of Cancer Foundation of China (LC2020A10).

**Acknowledgments**

The authors acknowledge the transparency of the program and all those who have worked and continue to work on it.

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publishers, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.1063031/full#supplementary-material

SUPPLEMENTARY FIGURE 1
The top 10 biological pathways negatively correlated with high RARG expression.

References

1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin (2016) 66(2):115–32. doi:10.3332/caac.213388
2. Yang X, Li Y, Cai SQ, Wang L, Qian JW. The global burden of breast cancer in women. Cancer Cells (2017) 4(6):2285–99. doi:10.1016/j.ccell.2017.06.006
3. Global Burden of Disease Cancer Collaborators. Cancer in China. CA Cancer J Clin (2017) 67(2):92–111. doi:10.3322/caac.213743
4. Paik ES, Lee YY, Choi CH, Kim TJ, Lee JW, et al. Survival analysis of revised 2013 FIGO staging classification of epithelial ovarian cancer and comparison with previous FIGO staging classification. Obstet Gynecol Sci (2015) 58(2):124–34. doi:10.5468/ogs.2015.58.2.124
5. Kommos S, Schmidt D, Kommos F, Hedderich J, Harter P, Pfisterer J, et al. Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol). Virchows Arch (2009) 455(3):249–56. doi:10.1007/s00428-009-0725-y
6. Germain P, Chambon P, Eichele G, Evans RM, Lazar MA, Leid M, et al. International union of pharmacology. LX. retinoic acid receptors. Pharmacol Rev (2006) 58(4):712–25. doi:10.1124/pr.58.4.4
7. Altucci L, Lebowitz MD, Ogilvie KM, de Lera AR, Gronemeier H. RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discovery (2007) 6(10):793–810. doi:10.1038/nrd2397
8. le Maire A, Teyssier C, Balaguer P, Bourguet W, Germain P. Regulation of RXR-RAR heterodimers by RXR- and RAR-specific ligands and their combinations. Cell (2009) 137(11):1392. doi:10.1016/j.cell.2009.07.018
9. Han YH, Zhou H, Kim JH, Yan TD, Lee KH, Wu H, et al. A unique cytoplasmic localization of retinoic acid receptor-gamma and its regulations. J Biol Chem (2009) 284(27):18503–14. doi:10.1074/jbc.M109.007718
10. Gan WJ, Wang JR, Zhu XL, He XS, Guo PD, Zhang S, et al. RARGamma-induced e-cadherin downregulation promotes hepatocellular carcinoma invasion and metastasis. J Exp Clin Cancer Res (2016) 35(1):164. doi:10.1186/s13046-016-0441-9
11. Ma Z, Guo W, Niu HJ, Yang F, Wang RW, Jung YG, et al. Transcriptome network analysis reveals potential candidate genes for esophageal squamous cell carcinoma. Asian Pac J Cancer Prev (2012) 13(3):767–73. doi:10.7314/ APJCPR.2012.13.3.767
12. Petrie K, Urban-Wojcik Z, Shirkov Y, Graham A, Hamann A, Brown G. Retinoic acid receptor gamma is a therapeutically targetable driver of growth and survival in prostate cancer. Cancer Res (Hoboken) (2020) 3(6):e1284. doi:10.1002/crn2.1284
13. Yang D, He Y, Wu B, Denga Y, Wang N, Li M, et al. Integrated bioinformatic analysis for the screening of hub genes and therapeutic drugs in ovarian cancer. J Ovarian Res (2020) 13(1):1. doi:10.1186/s13048-020-0613-2
14. Gupta KK, Gupta VK, Naumann RW. Ovarian cancer: screening and future directions. Int J Gynecol Cancer (2019) 29(1):195–200. doi:10.1136/ijgc-2018-000016
15. Reid BM, Permutt JB, Sellers TA. Epidemiology of ovarian cancer. A review. Cancer Biol Med (2017) 14(1):9–32. doi:10.20892/nrms.2095-3941.2016.0084
16. Wei SU, Li H, Zhang B. The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer. BioMed Res Int (2016) 5(1):41–4. doi:10.3882/bmri.2016.682
17. Guo YX, Neoh KH, Chang XY, Sun Y, Cheng HY, Ye X, et al. Diagnostic value of HE4+ circulating tumor cells in patients with suspicious ovarian cancer. Oncotarget (2018) 9(7):7522–33. doi:10.18632/oncotarget.23943
18. Tang Q, Chen Y, Meyer C, Geidtlinger T, Lupien M, Wang Q, et al. A comprehensive view of nuclear receptor cancer cistromes. Cancer Res (2011) 71(22):6940–7. doi:10.1158/0008-5472.CAN-11-2091
19. Huang GL, Song W, Zhou P, Pu QR, Lin CL, Chen QX, et al. Oncogenic retinoic acid receptor gamma knockdown reverses multi-drug resistance of human colorectal cancer via wnt/beta-catenin pathway. Cell Cycle (2017) 16(7):685–92. doi:10.1080/15352472.2017.1295180
20. Huang GL, Luo Q, Rui G, Zhang W, Zhang QT, Chen QX, et al. Oncogenic activity of retinoic acid receptor gamma is exhibited through activation of the Akt/NF-kappaB and wnt/beta-catenin pathways in cholangiocarcinoma. Mol Cell Biol (2013) 33(17):3416–25. doi:10.1128/MCB.00384-13
21. Yan TD, Wu H, Zhang HP, Lu N, Ye P, Yu FH, et al. Oncogenic potential of retinoid acid receptor-gamma in hepatocellular carcinoma. Cancer Res (2010) 70(6):2285–95. doi:10.1158/0008-5472.CAN-09-2968
22. Zeng W, Zhang C, Cheng H, Wu YL, Liu J, Chen Z, et al. Targeting to the non-genomic activity of retinoic acid receptor-gamma by acacetin in hepatobiliary carcinoma. Sci Rep (2017) 7(1):348. doi:10.1038/s41598-017-00233-5
23. Kumar A, Kaur J, Chattopadhyay TK, Mathur M, Rallan R. Differential expression of retinoic acid receptors in normal and malignant esophageal tissues. J Exp Ther Oncol (2004) 1(4):1–8. doi:10.4103/jeto.2003.12.002
24. Zhao X, Graves C, Ames SJ, Fisher DE, Spanjaard RA. Mechanism of regulation and suppression of melanoma invasiveness by novel retinoid acid receptor-gamma target gene carboxylate sulfotransferase 18. Cancer Res (2009) 69(12):5218–25. doi:10.1158/0008-5472.CAN-09-0705
25. Chen CF, Goyette P, Lohnes D. RARalpha acts as a tumor suppressor in mouse keratinocytes. Oncogene (2004) 23(11):5550–9. doi:10.1038/sj.onc.1207682
26. Guo PD, Lu X, Gan WJ, Li XM, He XS, Zhang S, et al. RARGamma downregulation contributes to colorectal tumorigenesis and metastasis by derepressing the hippo-yap pathway. Cancer Res (2016) 76(13):3813–25. doi:10.1158/0008-5472.CAN-15-2882
27. Brown G, Petrie K. The RARGamma oncoprotein: An Achilles heel for some cancers. Int J Mol Sci (2021) 22(7):362. doi:10.3390/ijms2207362
28. Purton LE, Dwookin S, Olsen GH, Walkley CR, Fahb SA, Collins SJ, et al. RARGamma is critical for maintaining a balance between hematopoietic stem cell self-renewal and differentiation. J Exp Med (2006) 203(5):1283–93. doi:10.1084/ jem.20052105
29. Wang Q, Lin Z, Wang Z, Ye L, Xian M, Xiao L, et al. RARGamma activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway. Blood (2022) 139(1):59–72. doi:10.1182/ blood.2020089556
30. Keedwell RG, Zhao Y, Hammond LA, Wen K, Qin S, Atangan LI, et al. An antagonist of retinoic acid receptors more effectively inhibits growth of human prostate cancer cells than normal prostate epithelium. Br J Cancer (2004) 91(3):380–8. doi:10.1038/sj.bjc.6602024